Multicentric cross-over trial to assess the glycemic profiles on 8 weeks of vildagliptin and sitagliptin treatment, each, in type-2 diabetic patients with a pre-existing cardiovascular disease pre-treated with insulin, using a PROBE-design
Phase of Trial: Phase IV
Latest Information Update: 07 Oct 2015
At a glance
- Drugs Vildagliptin (Primary) ; Insulin; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms CGM-visit
- Sponsors Novartis
- 07 Jun 2017 Biomarkers information updated
- 20 Sep 2014 According to the European Clinical Trials database record, status changed from active, no longer recruiting to completed.
- 04 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.